康弘药业：布瑞哌唑片获药品注册证书用于治疗成人精神分裂症

Core Viewpoint - Kanghong Pharmaceutical (002773) has received the drug registration certificate for Brivaracetam tablets from the National Medical Products Administration, enhancing its product pipeline [1] Group 1: Product Approval - Brivaracetam is indicated for the treatment of schizophrenia, with an unclear mechanism of action potentially involving partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, as well as antagonist activity at serotonin 5-HT2A receptors [1] - The approved specifications for Brivaracetam tablets are 1mg and 2mg, classified as a chemical drug of category 4 [1] Group 2: Impact on Company - The approval of Brivaracetam tablets enriches the company's product pipeline, indicating a strategic move to expand its offerings in the psychiatric treatment market [1]